普洛药业(000739) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥2,565,126,389.01, representing a year-over-year increase of 20.88%[3] - Net profit attributable to shareholders for Q3 2022 was ¥220,292,993.64, up 5.54% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥244,796,455.99, showing a significant increase of 44.21% year-over-year[3] - Total operating revenue for Q3 2022 reached ¥7,550,804,383.47, an increase of 17.98% compared to ¥6,399,153,386.70 in the same period last year[13] - Net profit for Q3 2022 was ¥657,091,282.69, a decrease of 13.81% from ¥762,133,599.43 in Q3 2021[14] - Total profit for Q3 2022 was ¥765,962,199.28, down 14.85% from ¥899,545,208.98 in the same quarter last year[14] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥11,157,718,538.84, reflecting a growth of 21.76% from the end of the previous year[3] - As of September 30, 2022, the total assets of the company reached CNY 11.16 billion, an increase from CNY 9.16 billion at the beginning of the year, representing a growth of approximately 21.8%[11] - The company's total liabilities increased, with short-term borrowings rising by 69.18% to ¥562,490,104.30 compared to the previous year[6] - The total liabilities of the company were CNY 5.97 billion, compared to CNY 4.10 billion at the beginning of the year, marking an increase of around 45.5%[12] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥870,772,728.39, an increase of 31.74% compared to the same period last year[6] - Cash inflow from operating activities totaled ¥6,008,821,887.45, an increase of 19.5% from ¥5,029,206,843.86 year-on-year[15] - The net increase in cash and cash equivalents for the quarter was ¥357,478,983.53, compared to ¥49,549,859.45 in the same quarter last year[16] - The ending balance of cash and cash equivalents reached ¥2,156,631,616.93, up from ¥1,973,988,633.38 at the end of the previous period[16] Research and Development - Research and development expenses for the first nine months of 2022 were ¥405,006,874.25, which is a 25.98% increase year-over-year[6] - Research and development expenses rose to ¥405,006,874.25, representing a 25.94% increase from ¥321,495,631.04 in the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,851, with the largest shareholder holding 28.08% of the shares[7] Operational Efficiency and Future Plans - The company has plans for market expansion and new product development, although specific details were not provided in the report[12] - The report indicates a focus on enhancing operational efficiency and exploring strategic partnerships to drive future growth[12] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 4.24%, a decrease of 0.18% compared to the previous year[3] - Earnings per share (EPS) for Q3 2022 was ¥0.5594, down from ¥0.6467 in Q3 2021, reflecting a decrease of 13.46%[14] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,369,975.63 compared to ¥37,930.80 in the previous year[14]